Wang, Yu-xiang http://orcid.org/0000-0002-5275-1709
Zhang, Xu http://orcid.org/0000-0002-3662-7759
Ma, Qing-yang
Hu, Lan-dian
Zhang, Xi
Wang, Yi
Xu, Lan
Yang, Chun-hao
Tan, Cun
Kong, Xiang-yin
Ding, Jian
Meng, Ling-hua http://orcid.org/0000-0001-7722-8685
Article History
Received: 24 August 2020
Revised: 13 December 2020
Accepted: 18 December 2020
First Online: 14 January 2021
Funding
: This work was supported by “Personalized Medicines-Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12020111, XDA12010204, & XDA12050407), National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program” (2018ZX09711002-011-014), National Natural Science Foundation of China (81773760 & 81973345) and Project funded by China Postdoctoral Science Foundation (2019M661668).
: The study did not require ethical approval.
: J.D. is the director of Shanghai HaiHe Pharmaceutical Co. Ltd.